2023年欧洲专家实验室SARS-CoV-2分子检测及变异分型外部质量评估
84%实验室全部正确识别,正确率较2020年(12%)和2021年(75%)提升至90%,商业试剂使用渐增,参与实验室数减少。
要点
- SARS-CoV-2样本正确检测率从2020年12%、2021年75%升至2023年90%。
- 商业试剂使用占58%,自建法29%,两者兼用13%,商业试剂使用渐增。
核心结论
- 三次连续EQA显示欧洲专家公共卫生实验室SARS-CoV-2分子诊断能力显著提升。
- 通过EQA常规监测诊断与监测方法对维持快速公共卫生实验室响应体系仍很关键。
研究设计与样本
- 样本盘含10个样本:Alpha(既往EQA使用)、BA.4、BA.5、BQ.1.18变异株、人季节性冠状病毒及阴性对照。
- 参与者通过电子表格提交结果和方法细节。
主要发现
- 32家(84%)实验室正确识别全部样本盘样本。
- 使用方法:自建法11家(29%)、商业试剂22家(58%)、两者兼用5家(13%)。
- SARS-CoV-2样本正确检测率:2020年8家(12%)、2021年45家(75%)、2023年34家(90%)。
- 参与实验室数降至平均每国1家(范围1-3),既往两次EQA为2家(1-7)。
- 商业试剂使用逐渐增加,自建法或两者兼用减少。
临床怎么用
- 实验室可通过EQA客观评估检测系统性能,及时发现弱点并改进。
- 应常规参与EQA以维持SARS-CoV-2分子检测和变异监测的准确性与可比性。
局限性
- 参与实验室数降至平均每国1家(范围1-3),较既往减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic highlighted the importance of laboratory preparedness. Regular monitoring of diagnostic tools via external quality assessments (EQAs) is key to maintaining robust public health response service. We hereby conducted a third SARS-CoV-2 EQA assessing the diagnostic capabilities of European expert public health laboratories. A 10 samples panel containing Alpha (used in previous EQA), BA.4, BA.5, and BQ.1.18 variants along with human seasonal coronaviruses and negative controls was produced and validated. Participants were invited by the European Centre for Disease Prevention and Control (ECDC) and asked to submit results and assay details via electronic forms. Thirty-eight laboratories from 31 European countries participated. Most (n = 32, 84%) identified all panel samples correctly and used in-house (11, 29%), commercial assays (22, 58%), or both (5, 13%). Compared to previous EQAs, correct detection of the SARS-CoV-2 samples in the panels increased: 8 (12%) in 2020, 45 (75%) in 2021, and 34 (90%) laboratories in 2023, respectively. The number of participants decreased to an average of one laboratory per country (range 1-3) compared to two (1-7) laboratories in both previous EQAs. The usage of commercial assays gradually increased in contrast to the usage of in-house or both approaches. The capacity for SARS-CoV-2 molecular diagnostics has markedly improved in Europe as evidenced by three consecutive EQAs carried out by expert public health laboratories. Routine monitoring of diagnostic and surveillance assays via EQAs remains key to maintaining rapid public health laboratory response systems.IMPORTANCEExternal quality assessments (EQAs) are crucial to ensure the reliability and consistency of diagnostic laboratories. They provide an objective framework for evaluating the performance of testing systems, enabling laboratories to identify weaknesses and implement improvements promptly. In the context of SARS-CoV-2, EQAs have become even more critical due to the high demand for accurate molecular diagnostics and the emergence of new variants. Accurate detection and typing of variants are especially essential for monitoring viral evolution. EQAs help standardize methodologies, ensuring that results across laboratories remain comparable and trustworthy. Moreover, they play a pivotal role in minimizing errors such as false positives or negatives. In this rapidly evolving landscape, regular EQAs are indispensable for maintaining high-quality standards in molecular diagnostics and variant surveillance. We demonstrate here that regular EQAs improve the molecular detection of SARS-CoV-2 in European laboratories.
引用
- Heimsch KC, Stanoeva KR, Mögling R, et al. External quality assessment of molecular detection and variant typing of SARS-CoV-2 in European expert laboratories in 2023. J Clin Microbiol. 2025. PMID: 40084838. doi:10.1128/jcm.01538-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。